Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1M | 43K | 0 | 0 | 0 |
| Gross Profit | 796K | 43K | 0 | 0 | 0 |
| Operating Income | -13M | -11M | -11M | -10M | -6M |
| EBITDA | -13M | -11M | -11M | -10M | -5M |
| Net Income | -11M | -9M | -10M | -10M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.92
+3.25% today
1Y Change
-34.75%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RenovoRx, Inc. (RNXT) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $0.92 and down 34.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +2511.6%, EPS growth of +13.5%, a dividend yield of 0.0%. What stands out right now is revenue +2511.6%, EPS +13.5%, free cash flow -20.1% with operating margin -1114.0% and ROIC -204.0%. Valuation already assumes a fairly strong business story at price/sales 27.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RNXT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNXT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RNXT Max Drawdown
-48.38%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RNXT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$6.3M
+36.1% YoY
Free Cash Flow
-$5.9M
+32.7% YoY
Revenue Growth
+2511.6%
EPS Growth
+13.5%
Gross Margin
70.9%
Net Margin
-994.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1M | 43K | 0 | 0 | 0 |
| Gross Profit | 796K | 43K | 0 | 0 | 0 |
| Operating Income | -13M | -11M | -11M | -10M | -6M |
| EBITDA | -13M | -11M | -11M | -10M | -5M |
| Net Income | -11M | -9M | -10M | -10M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7M | 7M | 1M | 4M | 15M |
| Total Assets | 8M | 8M | 1M | 7M | 16M |
| Total Liabilities | 3M | 4M | 4M | 1M | 938K |
| Shareholder Equity | 5M | 4M | -3M | 6M | 15M |
| Total Debt | 107K | 278K | 0 | 0 | 0 |
| Net Debt | -7M | -7M | -1M | -4M | -15M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+32.9% YoY
Capital Expenditures
15K
Free Cash Flow
6M
+32.7% YoY
Key ratios
Gross Margin
70.9%
Operating Margin
-1114.0%
Net Margin
-994.5%
ROE
-119.8%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.